Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.

Detalles Bibliográficos
Autores principales: Tambaro, Francesco Paolo, Khazal, Sajad, Nunez, Cesar, Ragoonanan, Dristhi, Tewari, Priti, Petropoulos, Demetrios, Kebriaei, Partow, Wierda, William George, Mahadeo, Kris Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495807/
https://www.ncbi.nlm.nih.gov/pubmed/32983475
http://dx.doi.org/10.1002/ccr3.2918
Descripción
Sumario:The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.

Ejemplares similares